FOXO4-DRI

LongevitySenolytic FOXO4 peptide / researchExperimental

D-retro-inverso peptide designed to disrupt FOXO4–p53 binding and clear senescent cells in mice (2017 Cell paper). No CAS as a registered drug; not FDA-approved. Often sold as Proxofim.

Calculate Dose

For research use only.

Key Facts

CAS: —
Molecular Weight (MW): —
Half-life: Experimental; not established
Unit: mcg
Administration Route: —
Frequency: —
Last updated: 8/23/2026
Targets: FOXO4–p53 interaction

Overview

D-retro-inverso peptide designed to disrupt FOXO4–p53 binding and clear senescent cells in mice (2017 Cell paper). No CAS as a registered drug; not FDA-approved. Often sold as Proxofim.

Protocol

Dosage Range: Not established (preclinical literature only)
Frequency: —
Cycle: —
Administration Route: —
Reconstitution Guide: —

Science

Mechanism of Action

Competes with FOXO4 for p53 in senescent cells, releasing p53 to trigger apoptosis preferentially in senescent fibroblasts in the original mouse study.